Kura Oncology to Participate in Two Upcoming Investor Conferences
May 30, 2017 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., May 30, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Reports First Quarter 2017 Operational and Financial Results
May 15, 2017 16:05 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., May 15, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (NASDAQ:KURA) a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Report First Quarter 2017 Financial Results
May 08, 2017 16:05 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Granted U.S. Patent for Clinical-Stage ERK Inhibitor, KO-947
April 19, 2017 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., April 19, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Kura Oncology Doses First Patient in Phase 1 Trial of ERK Inhibitor KO-947
April 07, 2017 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., April 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Kura Oncology Presents Preclinical Data Demonstrating Significant Anti-Tumor Activity of KO-947 and KO-539
April 05, 2017 08:00 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., April 05, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Preclinical Data for Kura Oncology Development Compounds to be Presented at AACR Annual Meeting 2017
March 29, 2017 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines, today announced...
Kura Oncology Reports Fourth Quarter and Full Year 2016 Operational and Financial Results
March 14, 2017 16:05 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., March 14, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (NASDAQ:KURA) a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Kura Oncology to Report Fourth Quarter and Full Year 2016 Financial Results
March 07, 2017 16:05 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Kura Oncology Reports Updated Clinical Activity Data in Ongoing Phase 2 Trial for Tipifarnib
March 06, 2017 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...